ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility

Core Insights - ADMA Biologics has repaid $30 million of its senior secured term loan facility, reducing total gross debt to$75 million, which represents a 29% reduction from previous levels [1][5] - The repayment was funded using cash on hand, indicating strong cash flow generation capabilities [2] - The company anticipates that the reduction in debt will lower interest expenses and enhance earnings growth potential in the near future [2] Company Overview - ADMA Biologics is a biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [2] - The company currently markets three FDA-approved plasma-derived biologics: BIVIGAM®, ASCENIV™, and NABI-HB® [2] - ADMA operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and has a subsidiary, ADMA BioCenters, that collects source plasma [2]